Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilarin Central and Eastern Europe.
Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilar in Central and Eastern Europe.
The proposed trastuzumab biosimilar will be seeking indications to treat human epidermal receptor 2 (HER2)-positive breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The potential biosimilar is currently in phase 3 clinical development and will be marketed as Hervelous.
“I am pleased to partner with Prestige BioPharma to further expand our biosimilar portfolio in the region… We have managed to secure a leading position in biosimilars in the region, with a robust portfolio of leading molecules for the treatment of oncology, rheumatoid arthritis, and anemia and the expected addition of [a] trastuzumab biosimilar will be a great addition to our biosimilar assets,” commented Hacho Hatchikian, executive vice president of Alvogen.
The agreement includes the exclusive rights for Alvogen to commercialize the proposed biosimilar in all of its Central and Eastern European markets. Although the exact terms of the arrangement have not been publicly disclosed, Prestige BioPharma will assume the responsibility of development and product registration with the European Medicines Agency (EMA), as well as the commercial supply of the biosimilar out of its manufacturing facilities in Osong, South Korea.
The companies plan to file with the EMA and the FDA for regulatory approval in 2019.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.